When stratifying the diagnostic category cancer into the three subtypes, myeloid diseases, lymphatic diseases, and solid tumor cancers, patients with Cbl levels >1000 pmol/L had higher risks of all three subtypes, with the highest risk for myeloid cancers. Here, CBL is linked to lymphatic system disorder.